Upper aerodigestive tract (UADT) cancers, predominantly squamous cell in origin, comprise the oral cavity, larynx, and esophagus. UADT cancers are the fourth most common cause of cancer death worldwide ([@CIT0001]). Consumption of tobacco and alcohol are established UADT cancer risk factors ([@CIT0002]), but genetic epidemiology ([@CIT0003]) and familial studies ([@CIT0004]) provide evidence for a role of genetic susceptibility in the pathogenesis of this disease.

Exposure to tobacco and alcohol leads to cell damage and DNA alterations that, in the absence of repair, may cause cell cycle deregulation and cancer development ([@CIT0005],[@CIT0006]). DNA repair genes, like *BRCA2*, play an important role in repair of DNA lesions ([@CIT0007],[@CIT0008]), and germline genetic variation affecting gene function may modulate disease risk. A recent imputation-based genome-wide association study of 21597 lung cancer case patients and 54 083 control patients identified a rare truncating *BRCA2* genetic variant, rs11571833 (K3326X), to be robustly associated with lung cancer. While present in lung adenocarcinomas (odds ratio \[OR\] = 1.47, *P* = 5x10^-4^), the association was more pronounced in lung squamous cell carcinomas (OR = 2.47, *P* = 10^--20^) ([@CIT0009]). As squamous cell carcinomas (SCCs) of different anatomical sites share many phenotypic and molecular characteristics ([@CIT0010]), the present study investigated rs11571833 in the context of genetic susceptibility to UADT cancers.

We explored rs11571833 in nine UADT cancer case-control studies (study designs and population characteristics have been described previously \[[@CIT0003],[@CIT0011],[@CIT0012]\]) totalling 5942 UADT cancer case patients and 8086 control patients ([Table 1](#T1){ref-type="table"}). Study participants underwent informed consent and approval by local and International Agency for Research on Cancer institutional ethics (IRB) review. rs11571833 was genotyped using Taqman (C\_\_27537307_30 Applied Biosystems, Carlsbad, CA), with operators blinded to case-control status, as described elsewhere ([@CIT0009]). Regenotyping samples of known genotype obtained by orthogonal genotyping techniques (90 Hapmap CEU samples where one individual was heterozygous) and direct DNA sequencing of Taqman-defined heterozygote individuals (n = 10) confirmed the fidelity of the Taqman assay. Internal study duplicate (approximately 8% from each study) concordance was over 99%. rs11571833 minor allele (T) was rare in Europe and Latin America, with a minor allele frequency in control patients of 0.50% and 0.62%, respectively, less prominent in the Indian subcontinent (0.27%) and extremely rare in Japan (only one single heterozygote observed in case patients and none in the 1203 control individuals). rs11571833 homozygote individuals were not observed, although none were expected given the variant frequency and genotype distributions expected under Hardy-Weinberg equilibrium. We used multivariable unconditional logistic regression with variables for sex and combinations of study and country included in the model as covariables. All statistical tests were two-sided. rs11571833 was strongly associated with UADT cancers (OR = 2.53, 95% CI = 1.89 to 3.38, two sided *P* = 3x10^-10^), with the minor allele carriers of *BRCA2* rs11571833 having an important 2.5-fold increased risk of UADT cancers ([Figure 1](#F1){ref-type="fig"}). Within the Central-European and alcohol-related cancers and genetic susceptibility in European head and neck cancer studies where genome-wide genotyping data were available, this association did not appear sensitive to cryptic population structure, as adjusting for genotype inferred genetic ancestry had little effect ([Supplementary Table 1](http://jnci.oxfordjournals.org/lookup/suppl/doi:10.1093/jnci/djv037/-/DC1), available online). rs11571833 has been previously associated with increased risk of squamous cell esophageal cancers ([@CIT0013],[@CIT0014]), a finding we replicated in an independent study population (OR = 3.30, *P* = 3x10^-4^) and extended to other UADT cancer subsites (*P* ~het~ =. 58) ([Figure 1](#F1){ref-type="fig"}). Serological HPV16E6 status has been defined for 514/856 of the oro-pharyngeal cancers presented here ([@CIT0015],[@CIT0016]); however, only two oro-pharyngeal cancers and one control patient were both HPVE6-positive and rs11571833 carriers. The association appeared consistent across the various studies (*P* ~het~ = .33) and by drinking status (*P* ~het~ = .63), although it appeared to vary somewhat by smoking status (*P* ~het~ = .026), with little evidence for association within never smokers. Where survival information was available (the ARCAGE study), there was a tendency for decreased overall survival in allele carriers compared with noncarriers (hazard ratio = 1.72, *P* = .05), although this result should be interpreted with caution as it is based on low numbers ([Supplementary Figure 1](http://jnci.oxfordjournals.org/lookup/suppl/doi:10.1093/jnci/djv037/-/DC1), available online).

###### 

Demographic characteristics of the case patients and control patients included in the genetic susceptibility study of *BRCA2* rs11571833 genetic variant\*

  -------------------------------------------------------------------------------------------------------------------------------------------------
                                                                          Case patients   Control patients   MAF control patients   MAF\
                                                                                                                                    case patients
  --------------------------------------- ------------------------------- --------------- ------------------ ---------------------- ---------------
  Study name/population characteristics   Study setting                                                                             

   ARCAGE                                  Europe - multicenter           1401            1505               0.006                  0.017

   Central-Europe                          Europe - multicenter           741             1652               0.005                  0.015

   Rome (HNI)                              Roma - Italy                   309             231                0.009                  0.024

   ACTREC                                  India                          220             358                0.010                  0.002

   Japan                                   Aichi Cancer Center Hospital   556             1203               0.000                  0.001

   SA                                      Latin America - multicenter    1493            1207               0.006                  0.011

   Oral cancer (ORC)                       Europe - multicenter           419             457                0.005                  0.013

   Oral cancer (ORC)                       India                          401             457                0.004                  0.012

   Poland                                  Szczecin - Poland              402             1016               0.003                  0.011

  Sex                                                                                                                               

   Male                                                                   4584            5966               0.004                  0.012

   Female                                                                 1358            2120               0.005                  0.013

  Age group                                                                                                                         

   \<50 y                                                                 1091            1629               0.005                  0.013

   ≥50 y                                                                  4447            6456               0.004                  0.013

   Missing                                                                404             1                  0.000                  0.011

  Smoking status                                                                                                                    

   Never smokers                                                          847             2632               0.006                  0.005

   Ever smokers                                                           4686            4433               0.005                  0.014

    Former                                                                1145            1981               0.003                  0.013

    Current                                                               3485            2338               0.005                  0.014

    Missing                                                               56              114                0.009                  0.000

   Missing                                                                409             1021               0.003                  0.013

  Alcohol intake status                                                                                                             

   Never drinkers                                                         915             1927               0.004                  0.010

   Ever drinkers                                                          4614            5141               0.005                  0.013

    Former                                                                720             508                0.007                  0.017

    Current                                                               2575            2514               0.004                  0.011

    Missing                                                               1319            2119               0.006                  0.014

   Missing                                                                413             1018               0.003                  0.013

   Site of tumor                                                                                                                    

   Oral cavity                                                            2230                                                      0.011

  Oropharynx                              856                                                                0.013                  

  Larynx/hypopharynx                      2195                                                               0.014                  

   Esophagus                                                              635                                                       0.012

   Missing                                                                26                                                        0.019
  -------------------------------------------------------------------------------------------------------------------------------------------------

\* ACTREC = Advanced Centre for Treatment, Research and Education in Cancer oral cancer study; ARCAGE = Alcohol Related CAncers and Genetic susceptibility in Europe; HNI = Rome (Italy) head and neck cancer study; MAF = minor allele frequency; ORC= IARC multicentre oral cancer case control study; SA = South America.
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While less common than cancers of the prostate, pancreas, and ovary, some excess of laryngeal and pharyngeal cancers have also been reported in *BRCA2* mutation--positive families ([@CIT0017],[@CIT0018]), implying a potential role for deleterious *BRCA2* mutations in UADT cancer genetic susceptibility. Germline mutations in the *BRCA2* gene have also been implicated in Fanconi Anemia ([@CIT0019]), which includes UADT cancers within its disease spectrum ([@CIT0020],[@CIT0021]). We did not identify any additional deleterious germline *BRCA2* mutations in our genetic analysis of the germline exome sequences of 10 head and neck squamous cell (HNSC) carcinomas in carriers of rs11571833 identified by The Cancer Genome Atlas (TCGA) initiative. Although numbers are small, these observations, together with similar ones made in 24 rs11571833 lung cancer carriers ([@CIT0009]), suggest that linkage disequilibrium (LD) with additional *BRCA2* mutations appears unlikely to explain the association. rs11571833 encodes a truncated form of the BRCA2 protein, resulting in the loss of the final 93 amino acids and is not considered a high-risk breast cancer allele ([@CIT0022]). Consistent with this, in vitro studies suggest that K3326X does not have comparable functional consequences to the gene product as do the deleterious *BRCA2* breast cancer susceptibility alleles ([@CIT0023]). Somatic loss (somatic mutation or loss of heterozygosity) of the wild-type allele of the *BRCA2* gene was not observed in the 10 TCGA HNSC rs11571833 carriers: This is similar to lung cancer ([@CIT0009]), whereas this loss is common in *BRCA2* germline mutation--positive breast tumors.

The limitations of this study are the rarity of rs11571833, which constrains our statistical power to investigate the heterogeneity of the association across substrata or correlations with factors such as tumor loss of heterozygosity. Nor was it possible to rule out that rs11571833 is an LD proxy for a variant in another gene, although rs11571833 is itself a noteworthy variant in a relevant gene.

rs11571833 has been associated with pancreatic cancer ([@CIT0024]) and a modest but statistically significantly increased risk (26%) of breast cancer (OR = 1.26) ([@CIT0025]). The 2.5-fold increase in genetic risk noted for UADT cancer here and squamous cell lung cancers ([@CIT0009]) is markedly higher. The difference in risk, together with the ambiguous functional consequence of this variant, suggests an alternate susceptibility mechanism for K3326X compared with the highly deleterious *BRCA2* breast cancer susceptibility alleles. Nevertheless, although the population-attributable fraction remains modest (0.7%), a robust association between a truncating *BRCA2* variant and UADT cancer risk suggests that treatment strategies like PARP1 inhibitors or synthetic lethality approaches targeting *RAD52* and *BRCA2* ([@CIT0026],[@CIT0027]) may warrant further consideration in UADT tumors.
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